Your session is about to expire
← Back to Search
Chemotherapy
Parsaclisib for Non-Hodgkin's Lymphoma
Phase 1
Waitlist Available
Research Sponsored by Incyte Corporation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Men and women, aged 18 years or older on the day of signing the Informed Consent Form (ICF).
Histologically confirmed indolent/aggressive DLBCL, FL, MZL, or MCL.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to approximately 12 months.
Awards & highlights
Study Summary
This trial is testing a new drug to see if it is safe and effective when combined with other treatments for people with a certain type of lymphoma.
Eligible Conditions
- Non-Hodgkin's Lymphoma
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to approximately 12 months.
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to approximately 12 months.
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Number of treatment-emergent adverse events (TEAEs)
Secondary outcome measures
Apparent clearance of parsaclisibin combination with rituximab, bendamustine and rituximab, or ibrutinib
Apparent volume of distribution of parsaclisib in combination with rituximab, bendamustine and rituximab, or ibrutinib
Side effects data
From 2021 Phase 1 & 2 trial • 88 Patients • NCT0201886167%
Nausea
67%
Decreased appetite
67%
Vomiting
33%
Hypertension
33%
Musculoskeletal chest pain
33%
Constipation
33%
Pain in extremity
33%
Hypercalcaemia
33%
Diarrhoea
33%
Fatigue
33%
Lacrimation increased
33%
Pain in jaw
33%
Dehydration
33%
Arthralgia
33%
Asthenia
33%
Haemorrhoids
33%
Rash
33%
Weight increased
100%
80%
60%
40%
20%
0%
Study treatment Arm
Parsaclisib 30 mg + Itacitinib 300 mg
Parsaclisib 15 mg QD + R-ICE
Parsaclisib 20 mg + Itacitinib 300 mg
Parsaclisib 20 mg QD + R-ICE
Total
Parsaclisib 5 mg QD
Parsaclisib 10 mg QD
Parsaclisib 15 mg QD
Parsaclisib 20 mg QD
Parsaclisib 30 mg QD
Parsaclisib 45 mg QD
Trial Design
3Treatment groups
Experimental Treatment
Group I: Treatment CExperimental Treatment2 Interventions
Parsaclisib + Ibrutinib
Group II: Treatment BExperimental Treatment3 Interventions
Parsaclisib + Bendamustine + Rituximab
Group III: Treatment AExperimental Treatment2 Interventions
Parsaclisib + Rituximab
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Parsaclisib
2018
Completed Phase 2
~330
Rituximab
1999
Completed Phase 4
~1880
Bendamustine
2015
Completed Phase 3
~2950
Ibrutinib
2014
Completed Phase 3
~1880
Find a Location
Who is running the clinical trial?
Incyte CorporationLead Sponsor
362 Previous Clinical Trials
55,038 Total Patients Enrolled
Peter Langmuir, MDStudy DirectorIncyte Corporation
10 Previous Clinical Trials
979 Total Patients Enrolled
Cinthya Coronado, MDStudy DirectorIncyte Corporation
1 Previous Clinical Trials
17 Total Patients Enrolled
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger